Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4059-05 tirabrutinib monotherapy in Waldenström macroglobulinemia and lymphoplasmacytic lymphoma
jRCT2080223998Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tirabrutinib in Waldenström macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL), sponsored by Ono Pharmaceutical. Started Aug 2018; status: completed.
02
Drugs
tirabrutinib
03
Conditions
Waldenström macroglobulinemia (WM)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on jRCT2080223998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223998.